Parexel’s Leanne Larson and Matthew Gordon shared their thoughts on the growing importance of real world evidence (RWE) in clinical research and in regulatory approval. They also discussed how the COVID-19 pandemic has accelerated the adoption of RWE and put a spotlight on how real world data (RWD) […]
AMCP Partnership Forum on Biosimilars Identifies Adoption Challenges and RWE Solutions
The Academy of Managed Care Pharmacy (AMCP) Partnership Forum met in December 2020 to discuss the use of biosimilars in healthcare. The cross-disciplinary stakeholders examined barriers to biosimilar use in the United States and how real world evidence (RWE), among other strategies, can advance […]
Collaborative RWE Registry Promises Data Transparency
The Real World Evidence (RWE) Registry was formed by the International Society for Pharmacoeconomics and Outcomes (ISPOR), the International Society for Pharmacoepidemiology (ISPE), the National Pharmaceutical Council (NPC), and the Duke-Margolis Center for Health Policy. The registry is intended to […]
Newly Launched Cerner Enviza Utilizes RWD to Advance R&D, Improve Patient Outcomes, and Reduce Healthcare Costs
Cerner has launched Cerner Enviza, an operating unit that will use real world data (RWD) to advance clinical research and improve patient care. The initiative is also expected to reduce healthcare costs and improve health equity. Cerner President and CEO David Feinberg remarks, “The true promise […]
Savana CEO and Founder Discusses Overcoming RWE Challenges and Ensuring Data Privacy
Savana CEO and Founder discussed challenges that arise when designing real world evidence (RWE) studies, including data privacy concerns, data ownership, and performing high quality studies using artificial intelligence (AI). Savana has been remarkably successful in extracting useful real world data […]
RWE Brings Data Privacy Concerns and Solutions
The use of real world evidence (RWE) has put a spotlight on data privacy and regulatory concerns. Regulatory expert Jackie Mulryne and former European Medicines Agency legal advisor Alexander Roussanov share their thoughts on essential steps for RWE studies, including deidentifying patient data and […]
Investigators Use RWD to Identify Potential Alzheimer’s Drug
According to a new study using data from electronic health records (EHRs), bumetanide, a diuretic, could be used in patients with Alzheimer’s disease. The real world data (RWD) study sought to identify drugs already approved by the Food and Drug Administration (FDA) for other […]
ISPOR Article on the Growing Wearable Market and New Applications in Healthcare
A recent article featured in Value & Outcomes Spotlight details the growing use of wearables. These tools can be an important source of real world data (RWD) in clinical trials and in patients at risk of developing severe or worsening disease. In addition, payers are increasingly interested in […]
HealthVerity’s RWD Platform Informs Government Response to COVID-19
HealthVerity’s IPGE platform has been a critical source of real world data (RWD) for public health agencies throughout the COVID-19 pandemic, including the Centers for Disease Control (CDC) and the Food and Drug Administration (FDA). “Throughout the pandemic, public health agencies contracted […]
Register for Upcoming Webinar on RWD in Decentralized Clinical Trials
A webinar highlighting the benefits of decentralized clinical trials that incorporate real world data (RWD) will take place on November 1st at 12:00 PM EST. The webinar will feature important insights from leading data experts at EVERSANA, THREAD, Protocol First, and Datavant. “Decentralized […]
